Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameOcumension-B
Stock Code01477
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities中國眼科醫藥平台公司,致力於識別、開發和商業化同類首創或同類最佳的眼科療法,提供世界一流的藥物整體解決方案,以滿足中國眼科醫療的巨大需求缺口。
Listing Date2020-07-10
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國上海市靜安區石門一路211號旺旺大廈502-1室
Business Address (Hong Kong)香港銅鑼灣希慎道33號利園一期19樓1901室
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websiteocumension.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 14.66 / shares
Offer Price RangeFinal offer price only, no range
Lot Size500 shares
Entry ThresholdHK$ 7,330
Par ValueTo be extracted
Offer Period2020-06-29 to 2020-07-03
Global Offering Shares105,930,000 shares
HK Public Offer Shares (Initial)10,593,000 shares (10.0%)
Public Offer Lots (Initial)21,186lots (Pool A10,593lots,Pool B10,593lots)
International Placing Shares (Initial)95,337,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO575,250,620 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share49.9%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 1,552,933,800

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 500 HK$ 7,330
2 lots 1,000 HK$ 14,660
3 lots 1,500 HK$ 21,990
4 lots 2,000 HK$ 29,320
5 lots 2,500 HK$ 36,650
6 lots 3,000 HK$ 43,980
7 lots 3,500 HK$ 51,310
8 lots 4,000 HK$ 58,640
9 lots 4,500 HK$ 65,970
10 lots 5,000 HK$ 73,300
12 lots 6,000 HK$ 87,960
14 lots 7,000 HK$ 102,620
16 lots 8,000 HK$ 117,280
18 lots 9,000 HK$ 131,940
20 lots 10,000 HK$ 146,600
30 lots 15,000 HK$ 219,900
40 lots 20,000 HK$ 293,200
50 lots 25,000 HK$ 366,500
60 lots 30,000 HK$ 439,800
70 lots 35,000 HK$ 513,100
80 lots 40,000 HK$ 586,400
90 lots 45,000 HK$ 659,700
100 lots 50,000 HK$ 733,000
120 lots 60,000 HK$ 879,600
140 lots 70,000 HK$ 1,026,200
160 lots 80,000 HK$ 1,172,800
180 lots 90,000 HK$ 1,319,400
200 lots 100,000 HK$ 1,466,000
300 lots 150,000 HK$ 2,199,000
400 lots 200,000 HK$ 2,932,000
500 lots 250,000 HK$ 3,665,000
600 lots 300,000 HK$ 4,398,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
700 lots 350,000 HK$ 5,131,000
800 lots 400,000 HK$ 5,864,000
900 lots 450,000 HK$ 6,597,000
1,000 lots 500,000 HK$ 7,330,000
1,200 lots 600,000 HK$ 8,796,000
1,400 lots 700,000 HK$ 10,262,000
1,600 lots 800,000 HK$ 11,728,000
1,800 lots 900,000 HK$ 13,194,000
2,000 lots 1,000,000 HK$ 14,660,000
4,000 lots 2,000,000 HK$ 29,320,000
6,000 lots 3,000,000 HK$ 43,980,000
8,000 lots 4,000,000 HK$ 58,640,000
10,593 lots 5,296,500 HK$ 77,646,690

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 4.84B
Est. Threshold HK$ 9.69B
Analysis Result HK market cap below threshold, need +100%

Valuation & Financials

Market Cap (at Offer Price)HK$ 8,433,174,089
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不适用(公司处于亏损状态)
Profit/Loss Status亏损净额人民币1,325.5百万元
Period-End Cash Balance人民币192.4百万元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 20182019
Revenue 0812
Cost of sales 0-802
Gross profit 0813
Other income and gains, net 8568,537
Selling and distribution expenses 0-8,459
Administrative expenses -8,659-58,785
Operating profit -895,955-945,855
Net finance costs -965-963
Profit before tax -995,956-946,885
Income tax expense 00
Profit for the year -975,966-936,785
Profit attributable to owners -973,964-923,815
Balance Sheet
Item 20182019
Cash and cash equivalents 83,629983,814
Trade and bills receivables 8,46983,581
Inventories 8648,259
Total current assets 93,596937,994
Total assets 953,884954,984
Total current liabilities 8,444843,784
Total liabilities 834,9349,258,734
Total equity -793,034-9,130,438
Equity attributable to owners -914,024-9,210,428
Cash Flow Statement
Item 20182019
Net cash from operating activities -96,254-97,284
Net cash from investing activities -74,664-717,917
Net cash from financing activities 116,0911,140,655
Net increase in cash 45,707153,030
Depreciation of PP&E 15250
Depreciation of right-of-use assets 49958
Purchase of PP&E -278-766
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 37.0
First Day OpenHK$ 43.0
First Day Change152.39%
First Day Volume59068800.0
First Day Turnover2394770000.0
Use of Proceeds
1、約427.19百萬港元(即所得款項凈額的30.00%)將用于我們的核心產品OT401; 2、約711.98百萬港元(即所得款項凈額的50.00%)將用于其他候選藥物; 3、約142.40百萬港元(即所得款項凈額的10.00%)將用于根據我們與當地政府所訂合作協議收購蘇州的制造設施; 4、約142.40百萬港元(即所得款項凈額的10.00%)將用作營運資金及用于其他一般公司用途。

Underwriting Syndicate

Joint Sponsors (2)
Morgan Stanley Asia Limited CE AAD291 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536
Overall Coordinators (3)
Morgan Stanley Asia Limited CE AAD291 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 UBS Securities Hong Kong Limited CE BIN466
Joint Bookrunners (3)
Morgan Stanley Asia Limited CE AAD291 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 UBS Securities Hong Kong Limited CE BIN466
Joint Lead Managers (3)
Morgan Stanley Asia Limited CE AAD291 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 UBS Securities Hong Kong Limited CE BIN466

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Alpha Profit Holdings Limited 116,231,810 HKD — 7.48% — 6 months 2021-01-10
2 BlackRock Funds 38,739,050 HKD — 2.49% — 6 months 2021-01-10
3 Boyu Capital Opportunities Master Fund 38,739,050 HKD — 2.49% — 6 months 2021-01-10
4 Cormorant Asset Management, LP 38,739,050 HKD — 2.49% — 6 months 2021-01-10
5 Fidelity International 139,475,240 HKD — 8.98% — 6 months 2021-01-10
6 General Atlantic Singapore OT Pte. Ltd. 77,485,430 HKD — 4.99% — 6 months 2021-01-10
7 HBM Healthcare Investments (Cayman) Ltd. 23,243,430 HKD — 1.50% — 6 months 2021-01-10
8 Hudson Bay Master Fund LTD 38,739,050 HKD — 2.49% — 6 months 2021-01-10
9 Lake Bleu Prime Healthcare Master Fund Limited 54,242,000 HKD — 3.49% — 6 months 2021-01-10
10 Octagon Investments Master Fund LP 15,495,620 HKD — 1.00% — 6 months 2021-01-10
11 OrbiMed Funds 38,739,050 HKD — 2.49% — 6 months 2021-01-10
12 Rock Springs Capital Master Fund LP 38,739,050 HKD — 2.49% — 6 months 2021-01-10
13 SCC Growth V Holdco L, Ltd. 38,739,050 HKD — 2.49% — 6 months 2021-01-10
14 TLS Beta Pte. Ltd. 77,485,430 HKD — 4.99% — 6 months 2021-01-10

Directors & Management

PositionChinese nameEnglish Name
Chairman陳連勇—
Company Secretary季芸、孫佩真—
No director data available.

Major Shareholders

Major Shareholders & Holdings6 Dimensions Capital持股21.55%,蘇州通和二期持股15.88%,Summer Iris Limited持股13.60%,TLS Beta Pte. Ltd.持股9.47%,蘇州通和毓承持股6.81%等。
About this page

This page shows Ocumension-B (01477) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect